Fatty Acid Binding Protein 3, FABP3 Protein (Active)

Catalog# BRP1013

Lot # Check on the product label

Size 100 µg

Description

Recombinant full length human FABP protein with molecular weight 15 kDa.

Synonyms Fatty acid-binding protein 3, FABP3, Heart-type fatty acid-binding protein, H-FABP, Mammary-derived growth inhibitor, MDGI, Muscle fatty acid-binding protein, M-FABP, FABP11

Source E. Coli

Purity >95% by SDS-PAGE

Formulation Liquid

Concentration 1 mg/ml

Application

ELISA

SDS-PAGE

Other applications have not been tested.

The optimal dilutions should be determined by end user.

Storage buffer

Each vial contains 20 mM Tris-HCL, 140 mM NaCl, 2 mM EDTA (pH8.0) without preservative.

Storage & Expiration

Ship at 4℃. Upon receipt, aliquot and store at -20℃ or -80℃ for long term.

Avoid repeated freeze and thaw cycles.

Background

Heart-type fatty acid binding protein (hFABP) also known as mammary-derived growth inhibitor is a protein that in humans is encoded by the FABP3 gene. It is a small cytoplasmic protein (15 kDa) released from cardiac myocytes following an ischemic episode. Like the nine other distinct FABPs that have been identified, H-FABP is involved in active fatty acid metabolism where it transports fatty acids from the cell membrane to mitochondria for oxidation. H-FABP is a sensitive biomarker for myocardial infarction and can be detected in the blood within one to three hours of the pain. It is also the biomarker for heart injury. In addition to its diagnostic potential, H-FABP also has prognostic value. Alongside D-dimer, NT-proBNP and peak troponin T, it was the only cardiac biomarker that proved to be a statistically significant predictor of death or Mi at one year.

Reference

1. Kleine AH, Glatz JF, Van Nieuwenhoven FA, Van der Vusse GJ (October 1992). "Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man". Mol. Cell. Biochem. 116 (1–2): 155–62.

2. Tanaka T, Hirota Y, Sohmiya K, Nishimura S, Kawamura K (April 1991). "Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction". Clin. Biochem. 24 (2): 195–201.

3. Watanabe K, Wakabayashi H, Veerkamp JH, Ono T, Suzuki T (May 1993). "Immunohistochemical distribution of heart-type fatty acid-binding protein immunoreactivity in normal human tissues and in acute myocardial infarct". J. Pathol. 170 (1): 59–65.